NASDAQ:BJDX Bluejay Diagnostics Earnings Date & Estimates $0.58 -0.04 (-6.97%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$0.59 +0.00 (+0.34%) As of 10/23/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bluejay Diagnostics is estimated to report earnings on Friday, November 13, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 13, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Bluejay DiagnosticsBluejay Diagnostics is expected to post earnings of -$3,520.00 per share. In the same quarter a year earlier Bluejay Diagnostics reported -$4.04 per share. Bluejay Diagnostics last reported on August 12, 2026, posting -$1.12 per share and beating the -$3,520.00 consensus estimate.Consensus EstimatesConsensus EPS-$3,520.00Prior-Year EPS-$4.04Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.12 (Beat by +$3,518.88)Prepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Bluejay Diagnostics Earnings FAQ When does Bluejay Diagnostics report earnings? Bluejay Diagnostics (NASDAQ:BJDX) is estimated to report earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Bluejay Diagnostics? Analysts expect Bluejay Diagnostics to post earnings of -$3,520.00 per share for the quarter. Bluejay Diagnostics Earnings HeadlinesBluejay Diagnostics (NASDAQ:BJDX) Stock Falls 3.7% - Here's WhyOctober 21, 2026 | americanbankingnews.comBluejay Diagnostics, Inc. Completes Establishment of Manufacturing Site for Symphonytm CartridgesOctober 14, 2026 | marketscreener.comMA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 25 at 1:00 AM | Porter & Company (Ad)5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & AtaraSeptember 8, 2026 | rttnews.comBluejay Diagnostics federal healthcare partnership builds commercial pathway ahead of FDA clearanceSeptember 8, 2026 | msn.comBluejay Diagnostics, Lovell Team Up To Access U.S. Federal Healthcare MarketSeptember 8, 2026 | rttnews.comSee More Bluejay Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email. Email Address About Bluejay DiagnosticsBluejay Diagnostics (NASDAQ:BJDX) is a medical technology company focused on developing rapid, decentralized diagnostic solutions for use at the point of care. The company’s products are designed to help healthcare professionals obtain timely information from blood samples, supporting clinical decision-making in acute-care settings. Bluejay’s primary technology is the Symphony System, a compact analyzer and disposable testing platform intended to measure clinically relevant biomarkers from whole blood. The system is designed to provide results near the patient rather than requiring samples to be sent to a centralized laboratory. The company has focused its development efforts on applications such as sepsis and other conditions in which rapid assessment may assist with patient management. Bluejay Diagnostics is based in the United States and has directed its activities primarily toward the U.S. healthcare market. The company continues to develop and advance its Symphony platform and related diagnostic applications for hospitals, emergency departments, and other acute-care environments.View Bluejay Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-OffPalantir's Next Big Test Isn't a Partnership—It's the Numbers Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
